HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1574235PULM stock profile & AI dashboard →

13F Pro Quality Score

17.7/100

Rank #2,821 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

PULM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Pulmatrix, Inc. (PULM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PULM at 17.7/100 on a 32-signal composite quality model, placing it at rank #2,821 of 2,961 stocks — the bottom half of the AI-ranked universe. Top institutional holders of PULM by reported 13-F value include RENAISSANCE TECHNOLOGIES, BlackRock, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. PULM trades on the Nasdaq exchange and files with the SEC under CIK 1574235. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PULM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pulmatrix, Inc. directly from SEC EDGAR. Pulmatrix, Inc.'s 13F Pro composite quality score has ranged between 11 and 18 since 2026, currently 17.7 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-1.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

FY 2025
FY22 $6.1MFY23 $7.3MFY24 $7.8MFY25

Net Income

+46.0% YoY
$-5.2MFY 2025
FY22 $-18.8MFY23 $-14.1MFY24 $-9.6MFY25 $-5.2M

Operating Income

+47.1% YoY
$-5.2MFY 2025
FY22 $-18.9MFY23 $-14.7MFY24 $-9.8MFY25 $-5.2M

EPS (Diluted)

+46.2% YoY
$-1.41FY 2025
FY22 $-5.46FY23 $-3.87FY24 $-2.62FY25 $-1.41

Total Assets

-58.4% YoY
$4.1MFY 2025
FY22 $41.0MFY23 $34.0MFY24 $9.9MFY25 $4.1M

Op. Cash Flow

+49.3% YoY
$-5.4MFY 2025
FY22 $-19.4MFY23 $-16.0MFY24 $-10.7MFY25 $-5.4M

Free Cash Flow

FY 2025
FY22 $-19.4MFY23 $-16.7MFY24 $-11.1MFY25

Get alerted when PULM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Pulmatrix, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of PULM

Put PULM on your watchlist

Track score changes the day Pulmatrix, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is PULM a good stock to buy?

13F Pro's AI-powered analysis of Pulmatrix, Inc. (PULM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PULM are available on the PULM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PULM is classified as a small company.

Which hedge funds own PULM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PULM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pulmatrix, Inc.'s investment landscape.